<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687581</url>
  </required_header>
  <id_info>
    <org_study_id>HJW1602</org_study_id>
    <nct_id>NCT02687581</nct_id>
  </id_info>
  <brief_title>Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia</brief_title>
  <official_title>Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Salus University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effectiveness of a novel amblyopia treatment -&#xD;
      Intermittent occlusion therapy (IO-therapy) glasses (AmblyzTM) in treating severe amblyopia.&#xD;
&#xD;
      Children ages 3 to 8 years with severe amblyopia (visual acuity of 20/100 to 20/400 in the&#xD;
      amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour patching&#xD;
      group or 2) 12-hour IO-therapy glasses group.&#xD;
&#xD;
      The study also observe the effectiveness of IO-therapy glasses on two types of difficult&#xD;
      amblyopia: deprivation amblyopia associated with congenital or developmental cataract, and&#xD;
      myopic anisometropic amblyopia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children ages 3 to &lt; 8 years with severe/dense amblyopia (visual acuity of 20/100 to 20/400&#xD;
      in the amblyopic eye) will be enrolled and randomized into two groups: 1) standard 6-hour&#xD;
      patching group or 2) 12-hour IO-therapy glasses group.&#xD;
&#xD;
      Children ages 3 to &lt; 8 years with deprivation amblyopia associated with congenital or&#xD;
      developmental cataracts (visual acuity of 20/40 to 20/400 in the amblyopic eye) will be&#xD;
      enrolled.&#xD;
&#xD;
      Children ages 3 to &lt; 8 years with myopic anisometropic amblyopia will be enrolled into an&#xD;
      intermittent occlusion therapy glasses (AmblyzTM) group.&#xD;
&#xD;
      According to visual acuity, they will receive one of two IO-therapy glasses treatment&#xD;
      regimens: 1) If the amblyopic eye is between 20/40 to 20/80 inclusive, 4-hour IO-therapy&#xD;
      glasses or 2) If the amblyopic eye is between 20/100 to 20/400 inclusive, the child will&#xD;
      receive12-hour IO-therapy glasses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12± 1 weeks after treatment</time_frame>
    <description>Visual acuity measured with ATS-HOTV methods.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>12-hour IO-therapy Glasses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>wear IO-therapy glasses for 12-hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-hour patching</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>wear the eye patch for 6-hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IO-therapy Glasses</intervention_name>
    <description>12-hour of 50% intermittent occlusion therapy on the fellow eye.</description>
    <arm_group_label>12-hour IO-therapy Glasses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>patch</intervention_name>
    <description>6-hour of eye patch on the fellow eye</description>
    <arm_group_label>6-hour patching</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 3 to &lt; 8 years&#xD;
&#xD;
          2. Amblyopia associated with strabismus, anisometropia, or both&#xD;
&#xD;
          3. Visual acuity, measured in each eye without cycloplegia within 7 days prior to&#xD;
             enrollment using the ATS single-surround HOTV letter protocol as follows:&#xD;
&#xD;
               -  Visual acuity in the amblyopic eye between 20/100 and 20/400 inclusive&#xD;
&#xD;
               -  Visual acuity in the sound eye 20/32 or better&#xD;
&#xD;
          4. Spectacle correction (if applicable) for measurement of enrollment visual acuity must&#xD;
             meet the following criteria and be based on a cycloplegic refraction within 6 months:&#xD;
&#xD;
               -  Requirements for spectacle correction:&#xD;
&#xD;
               -  For patients meeting criteria for only strabismus i. Hypermetropia if corrected&#xD;
                  must not be undercorrected by more than +1.50 D spherical equivalent, and the&#xD;
                  reduction in plus sphere must be symmetric in the two eyes. Otherwise, spectacle&#xD;
                  correction is at investigator discretion.&#xD;
&#xD;
               -  For patients meeting criteria for anisometropia or combined-mechanism i.&#xD;
                  Spherical equivalent must be within 0.50 D of fully correcting the anisometropia&#xD;
                  ii. Hypermetropia must not be undercorrected by more than +1.50 D spherical&#xD;
                  equivalent, and reduction in plus must be symmetric in the two eyes iii. Cylinder&#xD;
                  power in both eyes must be within 0.50 D of fully correcting the astigmatism iv.&#xD;
                  Cylinder axis in the spectacle lenses in both eyes must be within 6 degrees of&#xD;
                  the axis of the cycloplegic refraction&#xD;
&#xD;
          5. Wearing optimal spectacle correction for a minimum of 4 weeks at the time of&#xD;
             enrollment.&#xD;
&#xD;
          6. Gestational age &gt; 34 weeks and birth weight &gt; 1500 grams&#xD;
&#xD;
          7. Parent willing to accept randomization&#xD;
&#xD;
          8. Parent willing to be contacted and has access to phone&#xD;
&#xD;
          9. Parent does not anticipate relocation outside area of active study site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Amblyopic eye has myopia worse than -3.00D spherical equivalent.&#xD;
&#xD;
               -  Previous amblyopia treatment within 6 months.&#xD;
&#xD;
               -  Prior intraocular or refractive surgery&#xD;
&#xD;
               -  Known skin reactions to patch or bandage adhesives&#xD;
&#xD;
               -  Systemic diseases that may cause reduced vision such as Down syndrome.&#xD;
&#xD;
        If patients are in the deprivation amblyopia category, the following criteria must be met&#xD;
        for the patient to be enrolled in the study:&#xD;
&#xD;
          1. Age 3 to &lt; 8 years&#xD;
&#xD;
          2. Amblyopia due to previous congenital or developmental cataract surgery.&#xD;
&#xD;
          3. Visual acuity, measured in each eye without cycloplegia within 7 days prior to&#xD;
             enrollment using the ATS single-surround HOTV letter protocol as follows:&#xD;
&#xD;
        a. Visual acuity in the amblyopic eye between 20/40 and 20/400 inclusive b. Visual acuity&#xD;
        in the sound eye 20/32 or better c. Inter-eye acuity difference ≥ 2 logMAR lines (i.e.,&#xD;
        amblyopic eye acuity at least 3 lines worse than sound eye acuity) d) Gestational age &gt; 34&#xD;
        weeks and birth weight &gt; 1500 grams e) Parent willing to be contacted and has access to&#xD;
        phone.&#xD;
&#xD;
        If patients are enrolled in the myopic anisometropia amblyopia category, the following&#xD;
        criteria must be met for the patients to be enrolled in the study.&#xD;
&#xD;
          -  Aged 3 to &lt;8 years&#xD;
&#xD;
          -  Best-corrected VA in the amblyopic eye of 20/40 to 20/400 inclusive&#xD;
&#xD;
          -  Best-corrected VA in the fellow eye of 20/40 or better&#xD;
&#xD;
          -  Magnitude of myopic anisometropia of &gt; 3.00 D&#xD;
&#xD;
          -  Intereye acuity difference of &gt; 3 logMAR lines&#xD;
&#xD;
          -  Amblyopia associated with myopic anisometropia&#xD;
&#xD;
          -  Has been wearing optimal spectacle correction for a minimum of four weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingyun Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingyun Wang, PhD</last_name>
    <email>jwang@salus.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Salus University</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyun Wang, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Salus University</investigator_affiliation>
    <investigator_full_name>Jingyun Wang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

